Answers are grounded in this paper and cite their sources.
Pathologic myofibroblasts (MFs) are pivotal effector cells in the development of persistent tissue fibrosis following parenchymal injury, and their activation and accumulation has been linked to a failure to phenotypically dedifferentiate and thus to resist apoptosis. The second messenger cyclic AMP (cAMP) has been shown to induce MF dedifferentiation and restore their sensitivity to apoptosis in vitro, but its endogenous role within MFs during fibrosis resolution in vivo has not been explored. To test the hypothesis that cAMP generation and signaling within fibroblasts is essential for fibrosis resolution, we leveraged the spontaneously resolving nature of the single-dose intrapulmonary and subcutaneous bleomycin models in mice with an inducible and fibroblast-specific abrogation of cAMP generation owing to deletion of the stimulatory G protein (Gαs). Abolishing cAMP generation in fibroblasts after peak lung fibrosis was established led to a failure of the resolution with single-cell RNA seq demonstrating conspicuous differences in pathway enrichment and cellular cross-talk not only in fibroblasts, but also within macrophages and epithelial cells. Spontaneous resolution of skin fibrosis in a model of scleroderma similarly required cAMP production in dermal fibroblasts. We conclude that cAMP generation within fibroblasts after tissue fibrosis has been established is required for its spontaneous resolution in the lung and skin. Our findings provide new insights into factors governing the outcome of tissue fibrosis as well as a mechanistic basis that helps to explain the therapeutic efficacy and ultimate potential of newly available and emerging cAMP-elevating agents.
No takes yet. Share an insight, caveat, or question.
Fortier et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: